-
公开(公告)号：USRE49873E1
公开(公告)日：2024-03-19
申请号：US17382969
申请日：2021-07-22
发明人： Varghese John , Dale E. Bredesen
IPC分类号： A61K31/7048 , A61K31/352 , A61K31/366 , C07D311/24 , C07D311/30
CPC分类号： A61K31/7048 , A61K31/352 , A61K31/366 , C07D311/24 , C07D311/30
摘要： In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid prodrug (e.g., galangin prodrug).
-
公开(公告)号：US20230382901A1
公开(公告)日：2023-11-30
申请号：US18248325
申请日：2021-10-08
发明人： Robert A. VOLKMANN , Jotham W. COE , Eric VERDIN , Rosalba PERRONE , Margaret JACKSON , Frederick R. NELSON , Elena SILVA , Steve FELSTEAD
IPC分类号： C07D405/14 , C07D401/14 , C07D487/04
CPC分类号： C07D405/14 , C07D401/14 , C07D487/04
摘要： Disclosed are heteroaryl amide inhibitors of CD38 and methods of making and using the same in disease and disorder treatment.
-
公开(公告)号：US20220265605A1
公开(公告)日：2022-08-25
申请号：US17428600
申请日：2020-02-05
IPC分类号： A61K31/37 , A61K31/4745 , A61P25/28 , A61K31/5377
摘要： In various embodiments compounds that induce and/or promote autophagy are provided as wells as methods of use thereof (e.g., in the prophylaxis or treatment of chronic pathologies associated with aging). In one illustrative, but non-limiting embodiments the compound(s) comprise, inter alia, coumarin 106.
-
公开(公告)号：US20210369750A1
公开(公告)日：2021-12-02
申请号：US17286131
申请日：2019-10-23
发明人： David Pereira , Thomas Weldon
IPC分类号： A61K31/706 , A61K31/194 , A61K31/09 , A61K9/00 , A61P39/00
摘要： Described herein are methods and compositions comprising nicotinamide riboside and alpha-ketoglutarate for treating frailty, for maintaining health, and for re-growing hair.
-
公开(公告)号：US20210222150A1
公开(公告)日：2021-07-22
申请号：US17054760
申请日：2019-05-28
发明人： Marius Walter
IPC分类号： C12N15/10 , C12N7/00 , C12N9/22 , C12N15/113
摘要： In various embodiments methods of utilizing gene drive constructs in asexual organisms such as viruses are provided. In certain embodiments the methods involve transfecting or infecting a cell with a modified DNA vims containing a gene drive construct; and infecting the cell with the target vims where the genome of said target DNA virus is modified by insertion of the gene drive construct into the genome of the target DNA virus and a population of modified target viruses (containing the gene drive construct) is produced.
-
公开(公告)号：US10449177B2
公开(公告)日：2019-10-22
申请号：US13213960
申请日：2011-08-19
申请人： Varghese John , Dale E. Bredesen
发明人： Varghese John , Dale E. Bredesen
IPC分类号： A61K31/4035 , A61K31/05 , A61K31/145 , A61K31/5513
摘要： The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.
-
公开(公告)号：US10328073B2
公开(公告)日：2019-06-25
申请号：US16054667
申请日：2018-08-03
申请人： Unity Biotechnology, Inc. , Buck Institute for Research on Aging , Mayo Foundation for Medical Education and Research
发明人： Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Alain Philippe Vasserot , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Darren J. Baker , Bennett G. Childs , Jan M. A. van Deursen
IPC分类号： A61K31/496 , A61P27/02 , A61P11/00 , A61P9/10 , A61K31/428 , A61K31/495 , A61K31/5377 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36 , A61K9/00
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
8.发明授权公开(公告)号：US10328058B2
公开(公告)日：2019-06-25
申请号：US15792593
申请日：2017-10-24
申请人： Mayo Foundation for Medical Education and Research , Unity Biotechnology, Inc. , Buck Institute for Research on Aging
发明人： Darren J. Baker , Marco Demaria , Albert Davalos , Bennett G. Childs , Jan M. A. van Deursen , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Nathaniel David , Remi-Martin Laberge , Judith Campisi
IPC分类号： A61P9/10 , A61K31/496 , A61K31/4178 , A61K31/404 , A61K31/428 , A61K31/4375 , A61K31/5377 , A61K9/00 , A61K31/4164 , A61K45/06 , A61K47/36 , C12N5/00
摘要： Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
-
公开(公告)号：US10258618B2
公开(公告)日：2019-04-16
申请号：US15955542
申请日：2018-04-17
申请人： Buck Institute for Research on Aging , Unity Biotechnology, Inc. , Mayo Foundation for Medical Education and Research
发明人： Remi-Martin Laberge , Judith Campisi , Marco Demaria , Nathaniel David , Darren J. Baker , James L. Kirkland , Tamar Tchkonia , Yi Zhu , Jan M. A. van Deursen
IPC分类号： A61K9/00 , A61K31/496 , A61K31/5377 , A61P11/00 , A61K31/428 , A61K31/495 , A61K31/404 , A61K31/4375 , A61K45/06 , A61K31/4178 , A61K31/728 , C12N5/00 , A61K47/36
摘要： Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
-
公开(公告)号：US20180346466A1
公开(公告)日：2018-12-06
申请号：US15548402
申请日：2016-02-17
发明人： Varghese John , Dale E. Bredesen
IPC分类号： C07D487/04 , C07D471/04 , A61P25/28
CPC分类号： A61K31/519 , A61K31/437 , A61K45/06 , A61P25/28 , C07D471/04 , C07D487/04 , A61K2300/00
摘要： In certain embodiments compounds (e.g., triazolopyrimidine(s) and/or triazolopyridine(s)) are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated cortisol levels). The compounds are useful in the treatment or prophylaxis of pathologies characterized by abnormal amyloid plaque and or tangle formation and/or deposition.
-
-
-
-
-
-
-
-
-
搜索结果
105 条记录 (耗时 0.05 秒)
